Literature DB >> 9566352

Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay.

T Palosuo1, M Lukka, H Alenius, N Kalkkinen, K Aho, P Kurki, R Heikkilä, M Nykänen, R von Essen.   

Abstract

BACKGROUND: The so-called antikeratin antibody (AKA) and the antiperinuclear factor (APF) that recognize proteins related to human epidermal filaggrin belong to the most specific serological markers of rheumatoid arthritis (RA). However, assays for the detection of AKA and APF are currently based on immunofluorescence, a method that is subject to arbitrary interpretation and inadequate standardization of the substrates.
METHODS: Proteins extracted from human epidermis were separated by reversed-phase high-performance liquid chromatography (HPLC). Filaggrin-containing fractions, identified in immunoblotting by monoclonal antifilaggrin antibodies, were then subjected to gel filtration HPLC and, finally, to a second reversed-phase HPLC step. Tryptic digestion, amino acid sequencing and mass spectrometry were used to confirm the identity of the purified protein. Filaggrin was used as antigen in enzyme-linked immunosorbent assay (ELISA) to measure IgG class antifilaggrin antibodies.
RESULTS: The filaggrin preparation obtained gave a single band in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, binding monoclonal antifilaggrin antibody in immunoblotting. Amino acid sequences of all 10 tryptic peptides analyzed were shown to originate from human filaggrin. Antifilaggrin antibody levels exceeded the 99th percentile level of 100 middle-aged blood donors in 26/55 (47%) RA sera. At a similar cutoff level 28/55 (51%) of the RA sera were positive in the AKA test. Of the 26 antifilaggrin-positive sera, 21 were also AKA-positive.
CONCLUSION: Human filaggrin can be purified by standard biochemical techniques, despite the heterogeneity of the protein, and used in ELISA for testing autoantibodies to filaggrin. The sensitivity of the assay equals that of the AKA test.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566352     DOI: 10.1159/000069460

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  14 in total

1.  Recognition of new citrulline-containing peptide epitopes by autoantibodies produced in vivo and in vitro by B cells of rheumatoid arthritis patients.

Authors:  Eszter Szarka; Fruzsina Babos; Anna Magyar; Krisztina Huber; Zoltán Szittner; Krisztián Papp; József Prechl; Judit Pozsgay; Zsuzsa Neer; Monika Ádori; György Nagy; Bernadette Rojkovich; Tamás Gáti; Judit Kelemen; Zsuzsanna Baka; Márta Brózik; Borbála Pazár; Gyula Poór; Ferenc Hudecz; Gabriella Sármay
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

2.  IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin.

Authors:  S Chapuy-Regaud; L Nogueira; C Clavel; M Sebbag; C Vincent; G Serre
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

3.  Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides.

Authors:  C Vincent; F de Keyser; C Masson-Bessière; M Sebbag; E M Veys; G Serre
Journal:  Ann Rheum Dis       Date:  1999-01       Impact factor: 19.103

4.  Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis.

Authors:  L Nogueira; M Sebbag; C Vincent; M Arnaud; B Fournié; A Cantagrel; M Jolivet; G Serre
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

5.  Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis.

Authors:  L Paimela; T Palosuo; K Aho; M Lukka; P Kurki; M Leirisalo-Repo; R von Essen
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

6.  Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis.

Authors:  Suk Woo Choi; Mi Kyoung Lim; Dong Hyuk Shin; Jeong Jin Park; Seung Cheol Shim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

Review 7.  Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?

Authors:  Zoltán Szekanecz; Lilla Soós; Zoltán Szabó; Andrea Fekete; Anikó Kapitány; Anikó Végvári; Sándor Sipka; Gabriella Szücs; Sándor Szántó; Gabriella Lakos
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

8.  Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.

Authors:  R Nissinen; M Leirisalo-Repo; R Peltomaa; T Palosuo; O Vaarala
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

9.  Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis.

Authors:  O Vittecoq; B Incaurgarat; F Jouen-Beades; J Legoedec; O Letourneur; D Rolland; G Gervasi; J F Ménard; A Gayet; P Fardellone; A Daragon; M Jolivet; X le Loët; F Tron
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis.

Authors:  Mariusz Puszczewicz; Cezary Iwaszkiewicz
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.